Physician profile
Anna Hurley
NPI 1902444045
$2,948.91
in general payments reported to CMS, 2019-2025
25 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.36 · 2024: $1,514 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,924.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,012.64 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $320.07 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $249.68 | 2024-2025 | Repatha, Otezla, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $184.34 | 2024-2025 | Trintellix |
| Exact Sciences Corporation | $182.87 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $124.71 | 2024-2025 | |
| Astellas Pharma US INC | $115.74 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.80 | 2024-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $82.69 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $73.14 | 2024 | Voquezna |
| Pfizer INC. | $65.41 | 2024 | |
| Novo Nordisk INC | $63.03 | 2024-2025 | Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $54.03 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $49.40 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Ironwood Pharmaceuticals, INC | $47.72 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $31.79 | 2024 | Ingrezza |
| Corcept Therapeutics | $25.19 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $23.25 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.04 | 2024 | Jardiance |
| Lilly USA, LLC | $22.02 | 2025 | Zepbound, Mounjaro |
| Collegium Pharmaceutical, INC. | $21.13 | 2024 | Belbuca |
| Merck Sharp & Dohme LLC | $20.73 | 2025 | Gardasil 9, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $19.66 | 2024 | Eliquis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.03 | 2025 | Rejoyn |
| Mylan Specialty L.P. | $15.80 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Hurley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.